Prescription

EQS-News: Successful completion of a record year for Redcare Pharmacy: growth 49%, adj. EBITDA margin up 3.7pp to 3%; guidance achieved in all its elements.

Retrieved on: 
Wednesday, March 13, 2024

Successful completion of a record year for Redcare Pharmacy: growth 49%, adj.

Key Points: 
  • Successful completion of a record year for Redcare Pharmacy: growth 49%, adj.
  • EBITDA margin 3% for full year 2023, +3.7pp vs. 2022, with major improvements in both DACH and International segments.
  • Full-year guidance for 2024: continuation of both fast sales growth (30-40%) and solidly positive margins (adj.
  • Following positive margins in all four quarters, (iii) the adjusted EBITDA margin for the full year was 3% (guidance range of 1.5% to 3%).

AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc.

Retrieved on: 
Monday, March 11, 2024

If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.

Key Points: 
  • If you purchased or acquired Amylyx securities, and/or would like to discuss your legal rights and options please visit Amylyx Pharmaceuticals, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than April 9, 2024.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 9, 2024

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points: 
  • The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
  • The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
  • In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

MaNaDr's Weight Management Program Makes Waves at World Obesity Day Walk 2024 in Singapore

Retrieved on: 
Friday, March 8, 2024

MaNaDr, the gold event sponsor, believes more than 500 attendees visited its’ booth to inquire about the weight management program.

Key Points: 
  • MaNaDr, the gold event sponsor, believes more than 500 attendees visited its’ booth to inquire about the weight management program.
  • “We were thrilled by the enthusiasm and level of engagement surrounding weight management at the event,” said MaNaDr chief executive officer and co-founder Dr. Siaw Tung Yeng.
  • Second, all our doctors in the program are certified family physicians with Singapore’s latest Basic Obesity Management Accreditations.
  • These activities are part of the global World Obesity Day, an annual event started in 2015 to increase worldwide awareness of obesity.

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

Retrieved on: 
Thursday, March 7, 2024

The event included presentations by members of the ARS Pharma management team and by two distinguished allergists, Dr. Jonathan Spergel, M.D., Ph.D. and Dr. Thomas B. Casale, M.D.

Key Points: 
  • The event included presentations by members of the ARS Pharma management team and by two distinguished allergists, Dr. Jonathan Spergel, M.D., Ph.D. and Dr. Thomas B. Casale, M.D.
  • Of the patients that do fill their prescription, 80-90% either do not carry or use their treatment as indicated.
  • In late-February, the Company announced positive clinical data from a Phase 2 trial evaluating neffy in adults with chronic spontaneous urticaria.
  • The webcast replay and accompanying slides from today’s investor event may be accessed through the Events & Presentations page in the Investors & Media section of the Company's website.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Thursday, March 7, 2024

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024

Net loss: Net loss for the fourth quarter 2023 was $79.6 million, compared to $55.0 million for fourth quarter 2022.

Key Points: 
  • Net loss: Net loss for the fourth quarter 2023 was $79.6 million, compared to $55.0 million for fourth quarter 2022.
  • Fourth quarter 2023 net loss included a non-cash charge related to stock-based compensation of $24.6 million compared to $6.7 million for fourth quarter 2022.
  • Phathom will host a conference call and webcast to discuss its fourth quarter and full year 2023 financial results and business highlights today, March 7, 2024, at 8:30 a.m.
  • Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Retrieved on: 
Thursday, March 7, 2024

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Visory Health Names Ronald McDonald House Charities® of St. Louis As Its First Charity Supporting Children Locally 

Retrieved on: 
Tuesday, March 5, 2024

Ronald McDonald House Charities® (RMHC) of St. Louis provides a home-away-from-home to families of seriously ill or injured children and supports organizations that serve the needs of children.

Key Points: 
  • Ronald McDonald House Charities® (RMHC) of St. Louis provides a home-away-from-home to families of seriously ill or injured children and supports organizations that serve the needs of children.
  • In 2023, the local charity served 465 families through the Ronald McDonald House® program, where 75% were from Missouri or nearby Illinois.
  • It also supported over 45,000 local and out-of-town visitors through the Ronald McDonald Family Room® program at area hospitals.
  • We’re excited to begin our work with the Ronald McDonald House Charities® where families and children’s lives are positively impacted every day,” said Susan Lang, CEO and founder of Visory Health.

TeleVox Takes Patient Relationship Management to the Next Level at HIMSS 24

Retrieved on: 
Tuesday, March 5, 2024

ORLANDO, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- TeleVox will showcase how its industry-leading omnichannel patient relationship management platforms address all stages of the patient journey to support better outcomes and experiences at HIMSS 24 (booths 5167 and 5678-02), held March 11-15 at the Orange County Convention Center in Orlando.

Key Points: 
  • ORLANDO, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- TeleVox will showcase how its industry-leading omnichannel patient relationship management platforms address all stages of the patient journey to support better outcomes and experiences at HIMSS 24 (booths 5167 and 5678-02), held March 11-15 at the Orange County Convention Center in Orlando.
  • “Patient relationship management addresses the full patient journey, focusing on digital front door, appointment management, care programs, and patient marketing,” said Vik Krishnan, President of TeleVox.
  • TeleVox’s Iris™ was debuted at HIMSS 23 and is an AI-driven omnichannel virtual assistant, designed to elevate the patient experience.
  • For more information about these offerings, please visit TeleVox at booth 5167 at HIMSS 24 or visit www.televox.com .